Bright Minds Biosciences (DRUG) Competitors $32.46 +0.47 (+1.47%) As of 05/20/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock DRUG vs. SYRE, PHVS, CRMD, NAGE, CVAC, BCAX, ELVN, ZYME, QURE, and CMRXShould you be buying Bright Minds Biosciences stock or one of its competitors? The main competitors of Bright Minds Biosciences include Spyre Therapeutics (SYRE), Pharvaris (PHVS), CorMedix (CRMD), Niagen Bioscience (NAGE), CureVac (CVAC), Bicara Therapeutics (BCAX), Enliven Therapeutics (ELVN), Zymeworks (ZYME), uniQure (QURE), and Chimerix (CMRX). These companies are all part of the "pharmaceutical products" industry. Bright Minds Biosciences vs. Spyre Therapeutics Pharvaris CorMedix Niagen Bioscience CureVac Bicara Therapeutics Enliven Therapeutics Zymeworks uniQure Chimerix Bright Minds Biosciences (NASDAQ:DRUG) and Spyre Therapeutics (NASDAQ:SYRE) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, media sentiment, analyst recommendations, risk and community ranking. Does the MarketBeat Community believe in DRUG or SYRE? Spyre Therapeutics received 12 more outperform votes than Bright Minds Biosciences when rated by MarketBeat users. CompanyUnderperformOutperformBright Minds BiosciencesOutperform Votes10100.00% Underperform VotesNo VotesSpyre TherapeuticsOutperform Votes22100.00% Underperform VotesNo Votes Does the media prefer DRUG or SYRE? In the previous week, Bright Minds Biosciences had 11 more articles in the media than Spyre Therapeutics. MarketBeat recorded 16 mentions for Bright Minds Biosciences and 5 mentions for Spyre Therapeutics. Spyre Therapeutics' average media sentiment score of 1.58 beat Bright Minds Biosciences' score of 1.39 indicating that Spyre Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bright Minds Biosciences 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Spyre Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do analysts rate DRUG or SYRE? Bright Minds Biosciences currently has a consensus price target of $83.25, indicating a potential upside of 156.47%. Spyre Therapeutics has a consensus price target of $53.40, indicating a potential upside of 246.75%. Given Spyre Therapeutics' higher probable upside, analysts clearly believe Spyre Therapeutics is more favorable than Bright Minds Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bright Minds Biosciences 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25Spyre Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25 Which has higher valuation & earnings, DRUG or SYRE? Bright Minds Biosciences has higher earnings, but lower revenue than Spyre Therapeutics. Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Spyre Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBright Minds BiosciencesN/AN/A-$2.06M-$0.36-90.17Spyre Therapeutics$890K1,042.98-$338.79M-$3.77-4.08 Which has more volatility & risk, DRUG or SYRE? Bright Minds Biosciences has a beta of -5.32, meaning that its share price is 632% less volatile than the S&P 500. Comparatively, Spyre Therapeutics has a beta of 2.78, meaning that its share price is 178% more volatile than the S&P 500. Do institutionals and insiders believe in DRUG or SYRE? 40.5% of Bright Minds Biosciences shares are held by institutional investors. Comparatively, 80.4% of Spyre Therapeutics shares are held by institutional investors. 42.7% of Bright Minds Biosciences shares are held by insiders. Comparatively, 15.4% of Spyre Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Is DRUG or SYRE more profitable? Bright Minds Biosciences' return on equity of -5.85% beat Spyre Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Bright Minds BiosciencesN/A -5.85% -5.68% Spyre Therapeutics N/A -210.01%-44.40% SummarySpyre Therapeutics beats Bright Minds Biosciences on 7 of the 13 factors compared between the two stocks. Get Bright Minds Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for DRUG and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DRUG vs. The Competition Export to ExcelMetricBright Minds BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$225.34M$6.55B$5.43B$8.48BDividend YieldN/A2.66%5.22%4.11%P/E Ratio-190.939.1426.8320.05Price / SalesN/A255.60393.98117.08Price / CashN/A65.8538.2534.62Price / Book5.546.546.874.61Net Income-$2.06M$143.51M$3.22B$248.19M7 Day Performance2.40%5.60%6.76%2.97%1 Month Performance1.79%10.06%13.66%16.58%1 Year Performance2,560.66%-0.86%18.27%8.16% Bright Minds Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DRUGBright Minds Biosciences3.7921 of 5 stars$32.46+1.5%$83.25+156.5%+2,878.0%$225.34MN/A-190.93N/APositive NewsEarnings ReportUpcoming EarningsSYRESpyre Therapeutics2.3648 of 5 stars$14.88-2.0%$53.40+258.9%-58.2%$896.91M$890,000.00-1.99100Positive NewsPHVSPharvaris1.3029 of 5 stars$16.69+0.8%$40.67+143.7%-16.5%$872.72MN/A-5.9630CRMDCorMedix2.1474 of 5 stars$12.75+3.8%$15.00+17.6%+153.9%$864.77M$82.55M-15.7430NAGENiagen BioscienceN/A$10.93-0.2%N/AN/A$860.96M$107.93M64.29120CVACCureVac3.7543 of 5 stars$3.87+4.0%$14.00+261.8%+25.9%$834.54M$535.18M7.04880News CoverageUpcoming EarningsBCAXBicara Therapeutics1.6511 of 5 stars$15.21+5.1%$32.00+110.4%N/A$829.49MN/A0.0032Positive NewsEarnings ReportAnalyst RevisionGap UpELVNEnliven Therapeutics2.5336 of 5 stars$16.85-0.1%$37.25+121.1%-27.6%$826.81MN/A-8.8750Earnings ReportAnalyst RevisionGap DownZYMEZymeworks3.5883 of 5 stars$11.82+0.9%$21.00+77.7%+38.4%$822.40M$93.38M-7.88460Positive NewsAnalyst ForecastInsider TradeGap UpQUREuniQure3.1455 of 5 stars$14.71+7.4%$37.82+157.1%+215.7%$805.76M$20.20M-2.97500Analyst UpgradeCMRXChimerix0.5627 of 5 stars$8.54flat$8.53-0.1%N/A$801.09M$212,000.00-9.0990Analyst Forecast Related Companies and Tools Related Companies Spyre Therapeutics Competitors Pharvaris Competitors CorMedix Competitors Niagen Bioscience Competitors CureVac Competitors Bicara Therapeutics Competitors Enliven Therapeutics Competitors Zymeworks Competitors uniQure Competitors Chimerix Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DRUG) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bright Minds Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bright Minds Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy DRUG Stock Free DRUG Stock Alerts